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Summary With an incidence of nearly 1%, epilepsy represents one of the most
frequent diseases in the population. Nevertheless substantial information gaps exist
as to the exact incidence, prevalence, therapy and particularly to associated ther-
apeutic success. Adequate studies are not performed on many of these issues which
are primarily beyond the current interests of the pharmaceutical industry.
An Internet-based knowledge management database is presented to illustrate
initial results of the online systemwith a focus onmedication and side effects (http://
www.ligaepilepsie.org/KnowledgeDB/index.htm).
Further, it is worth noting that this database was designed as a potential model for
similar projects in other medical fields.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Many aspects of the epidemiology, therapy, success
rates and side effects in children and adults with
epilepsy are not known exactly: for some epilepsies
no established and optimized standard-therapy is
available. Lengthy studies with a large number of* Corresponding author.
E-mail address: drstkoenig@aol.com (S.A. Koenig).
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.06.005patients are difficult to perform as they would be
very expensive, so ‘‘hard’’ data are missing for many
therapeutic regimes.1—4 This lack of evidence is
becoming more important, as an evidence-based
therapy is increasingly demanded by more and more
health insurance companies. One possibility to
bridge the gap between therapeutic options and
the current lack of a sufficient body of evidence
could be a structured knowledge management data-
base as suggested here.. Published by Elsevier Ltd. All rights reserved.
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epilepsy, the underlying approch could also be
model for other medical fields. Currently, much of
the available evidence comes from approval studies
for new antiepileptic drugs (AEDs). Supported by
pharmaceutical companies, these approval studies
typically focus on the effectiveness and tolerability
of new drugs, usually in comparison to one or two ofFigure 1 Netwothe standard drugs on a short-term basis of only
several months. In comparison, the knowledge man-
agement database has the potential to provide
comprehensive, independent, large-scale and
long-term data. Similar developments are on amuch
smaller scale: there are only two online databases,
one for the registration of genetically caused epi-
lepsies5 and a database for therapy evaluation inrk overview.
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Turkey.6Method
An overview of the system is shown in Figs. 1 and 2.
As well as the professional database and associated
web server to support medical practitioners, the
system is meant to provide an appropriate level of
information to patients and the general public via a
public web server. The public part of the database
will present a relevant summary of data in a sim-
plified manner but has not yet been launched at this
stage of the development of the database. Our
approach allows the information to be consolidated
in a central location based on the consistently
structured data collected by medical professionals.
The information provided back to the medical pro-
fessional provides considerable depth and breadth
of detail. Further analysis of the information pre-
sented can be performed.
The medical professional maintains patient
records on the local database. The results for an
individual patient can be printed out and kept with
the paper files in the local office of the participatingFigure 2 Relationalpractitioner if desired. The software is easy and
quick to use and demands a realistic amount of time
(under 5 min for entry) for anyone willing to parti-
cipate. In principle, the electronic record could
readily replace the hand written record of the
medical practitioner.
The local database was designed by analyzing the
structure of knowledge underpinning the diagnosis
and treatment of epilepsy (Figs. 3 and 4). The
standard information on the history, underlying dis-
ease, psychomotor development, school and profes-
sion of the patient is recorded. The seizure
classification (Fig. 3) and the EEG-findings are also
recorded (Fig. 3) and can also be described in full
text. The medication and its effect on seizure con-
trol are recorded along with side effects (Fig. 4).
The data from the local database is uploaded via
the Internet to the central server. Updates of the
software are automatically downloaded through
the Internet, as are the list of treatments. While
every patient and every institution are automati-
cally assigned a code by the system, personal infor-
mation is not uploaded to the central server,
thereby protecting the privacy of both the patient
and the practitioner. Data safety is guaranteed by
an anonymization of the patients data. The detaileddatabase scheme.
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Figure 3 Seizure details of patients.informations are only available by the attending
physician.
Thecurrentanalysis of thedata is alsoavailable via
the Internet and reporting will be more comprehen-
sive in the future. The database is meant to grow and
change according to the needs and interests of the
participants. Furthermore, it is possible to evaluate
the AEDs in current and past therapy. The next level
of the automatic report system will provide data onFigure 4 Past and cuthe individual AEDs as to their effectiveness, includ-
ing data on seizure free impact, and reduction in the
frequency of seizures of less than andmore than 50%.Results
The database has been designned for easy and
potentially world-wide use, as it is based on therrent medication.
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Table 1 Results of the database—seizure classifica-
tion
Epilepsy Seizure classification Patients
Generalised Tonic—clonic 124
Tonic 9
Clonic 4
Atonic 10
Myoclonic 21
Myoclonic—astatic 3
Absence 48
Total 219
Partial Psychomotor 93
Motor-signs 5
Benign focal 23
Partial onset—secondary
generalisation
67
Other 11
Total 199
Table 3 Results of the database–—AEDs in the therapy
of absences
Medication Count %
Carbamazepine 3 3.57
Clonazepam 1 1.19
Ethosuximide 15 17.86
Felbamate 1 1.19
Gabapentin 1 1.19
Lamotrigin 2 2.38
Phenobarbital 4 4.76
Phenytoin 3 2.38
Primidone 4 4.76
Valproate 49 58.33
Vigabatrin 2 2.38
Total 84 100
Table 4 Absence seizures by medication-current
therapyInternet. At this stage of development, however,
more than 90% of the patients in the database are
treated at the Children’s Hospital of the University
of Mannheim. Ten other instituitions entered 17
patients, the remaining patients were all seen at
our institution. It is not the purpose of this paper to
present the peculiarities of our own patients, but
rather to demonstrate the proof of concept and
global possibilities of the database. The following
reports (Tables 1—6) outline various views of the
substantive content of the current dadtabase.
Details of approximately 400 patients have been
recorded in the database. The example of the
absence seizures was selected to demonstrate the
different levels of the reports created by the data-
base. Table 3 shows an overview of the AEDs
deployed; Tables 4 and 5 divide the results into
current and past therapy, respectively.
As can be seen in the graphics, there was a change
in the therapy of absence seizures. Phenobarbital,
primidone, phenytoin and clonazepam disappeared
in therapy of absence seizures. Valproate and etho-
suximide have become established as the AEDs ofTable 2 Results of the database–—overview of the
syndromes
Syndromes
Type Patients
None selected 398
West 6
Lennox—Gastult 2
Other 12
Total 418
Medication Count %
Carbamazepine 2 4.67
Ethosuximide 8 19.05
Felbamate 1 2.38
Gabapentin 1 2.38
Lamotrigin 1 2.38
Valproate 28 66.67
Vigabatrin 1 2.38
Total 42 100
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Table 5 Absence seizures by medication–—past ther-
apy
Medication Count %
Carbamazepine 1 2.38
Clonazepam 1 2.38
Ethosuximide 7 16.68
Lamotrigin 1 2.38
Phenobarbital 4 9.52
Phenytoin 2 4.76
Primidone 4 9.52
Valproate 21 50
Vigabatrin 1 2.38
Total 42 100
Table 6 Absence—valproate—seizure free—current
therapy
Status Count %
Seizure free 17 60.71
Not seizure free 11 39.29
Total 28 100first choice, with valproate being used in 66.7% of
the current patients.Discussion
We acknowledge that the low percentage of
patients with absence seizure on lamotrigin is a
peculiarity of our institute.
The database is meant to grow in the next
months. Data of epilptic patients, their medication
and the therapeutic success will be added and not
only patients from the Children’s Hospital of theUniversity of Mannheimwill be encolsed. This means
also, that the significance of our data will increase.
At the next level of analysis, the individually
specified AEDs can be selected and an overview of
therapeutic success with this individual medication
can be displayed. This is exemplified for valproate in
Table 6.Conclusion
The intension of the knowledgemanagement system
based on up to date actual patient data is to help
bridge the gap between the low evidence available
for many therapeutic questions in the treatment of
epilepsy and the requirements of evidence-based
medicine, increasingly required by the health insur-
ance companies. The possibilities of automated
report systems are exemplified by the data from
our own institute. Additionally this database could
be a model for similar projects in other medical
fields.Acknowledgments
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